Machine Learning, EHR Data Predict Future Dementia Risk
Early diagnosis of dementia could lead to earlier treatment.
Related Articles
Unlocking Treatment Possibilities in PBC
For US Healthcare Professionals Rush University Medical Center Chicago, IL Liver Institute Northwest Seattle, WA Weill Cornell Medical College New York, NY Rush University Medical…
Emerging Treatment Options in Patients With Difficult-to-Treat Hypertension
A panelist discusses how resistant hypertension remains a significant clinical challenge requiring accurate diagnosis, lifestyle and pharmacologic optimization, and emerging therapies such as aprocitentan to…
Late-Breaking Data Suggest Nerandomilast Beneficial for Patients with IPF and PPF
The FIBRONEER-IPF and FIBRONEER-ILD data highlight nerandomilast’s efficacy and safety in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.
Dupilumab Improves HRQoL, Asthma Control Irrespective of Coexisting Type 2 Conditions
Results highlight dupilumab’s real-world benefit for asthma control in patients with and without coexisting chronic rhinosinusitis and/or nasal polyposis.
24-Month Findings on Macitentan, Tadalafil for Pulmonary Arterial Hypertension, with Kelly Chin, MD
This interview highlights the long-term, late-breaking results of the A DUE trial’s 24-month open-label extension on macitentan and tadalafil for PAH.
Pediatric Year in Review: New Therapies in Sickle Cell Disease, with Shaina Willen, MD
This interview at ATS 2025 features a discussion of a ‘Pediatric Year in Review’ presentation on new therapies for sickle cell disease.
Mepolizumab Reduces Exacerbation Risk, Healthcare Resource Utilization in COPD
Gerard Criner, MD, reviews findings from a secondary analysis of the phase 3 MATINEE trial of mepolizumab and looks ahead to the potential significance of…
American Thoracic Society International Conference
HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.
Subgroup Findings on Brensocatib for Non-Cystic Fibrosis Bronchiectasis, with James D. Chalmers, MBChB, PhD
This interview highlights the subgroup analysis findings of the ASPEN trial, specifically on brensocatib for non-cystic fibrosis bronchiectasis.
Optimizing nAMD and DME Treatment: Real-World Durability, and Fluid Outcomes with Second Generation Anti-VEGF Agents
HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.